1. Name and Address of Reporting Person

**Qiming U.S. Healthcare Fund II, L.P**

(Last) (First) (Middle)

11100 NE 8TH ST., SUITE 200

2. Issuer Name and Ticker or Trading Symbol

**Jasper Therapeutics, Inc. [JSPR]**

3. Date of Earliest Transaction (Month/Day/Year)

01/27/2023

4. If Amendment, Date of Original Filed

5. Relationship of Reporting Person(s) to Issuer

<table>
<thead>
<tr>
<th>Code</th>
<th>(A)</th>
<th>(D)</th>
<th>Date</th>
<th>Exercisable</th>
<th>Expiration Date</th>
<th>Title</th>
<th>Amount or Number of Shares</th>
</tr>
</thead>
<tbody>
<tr>
<td>V</td>
<td>P</td>
<td>2,666,666</td>
<td>01/27/2023</td>
<td></td>
<td></td>
<td>$1.5</td>
<td>8,519,648</td>
</tr>
</tbody>
</table>

6. Individual or Joint/Group Filing (Check Applicable Line)

- Form filed by One Reporting Person
- Form filed by More than One Reporting Person

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

 rule 10b5-1(c) Transaction Indication

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

<table>
<thead>
<tr>
<th>Code</th>
<th>(A)</th>
<th>(D)</th>
<th>Date</th>
<th>Exercisable</th>
<th>Expiration Date</th>
<th>Title</th>
<th>Amount or Number of Shares</th>
</tr>
</thead>
<tbody>
<tr>
<td>V</td>
<td>P</td>
<td>2,666,666</td>
<td>01/27/2023</td>
<td></td>
<td></td>
<td>$1.5</td>
<td>8,519,648</td>
</tr>
</tbody>
</table>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**

(e.g., puts, calls, warrants, options, convertible securities)

1. Name and Address of Reporting Person

**Qiming U.S. Healthcare Fund II, L.P**

(Last) (First) (Middle)

11100 NE 8TH ST., SUITE 200

1. Name and Address of Reporting Person

**Qiming U.S. Healthcare GP II, LLC**

(Last) (First) (Middle)

11100 NE 8TH ST., SUITE 200

1. Name and Address of Reporting Person

**MCDADE MARK**

(Last) (First) (Middle)

C/O QIMING U.S. VENTURES MANAGEMENT, LLC

11100 NE 8TH ST., SUITE 200
1. Name and Address of Reporting Person

**RIESCHEL GARY E**

(Street)  
BELLEVUE  
WA  
98004

(City)  
(State)  
(Zip)

**C/O QIMING U.S. VENTURES MANAGEMENT, LLC**

11100 NE 8TH ST., SUITE 200

(Street)  
BELLEVUE  
WA  
98004

(City)  
(State)  
(Zip)

**Explanation of Responses:**

1. The securities are directly held by Qiming U.S. Healthcare Fund II, L.P. ("Qiming"). The general partner of Qiming is Qiming U.S. Healthcare GP II, LLC ("Qiming GP"). Gary Rieschel and Mark McDade are the managing partners of Qiming GP and may be deemed to share voting and dispositive power over the shares held by Qiming. Each of Qiming GP and Messrs. Rieschel and McDade disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

**Remarks:**

Qiming U.S. Healthcare Fund II, L.P. By: Qiming U.S. Healthcare GP II, LLC, its general partner, By /s/ Mark McDade, Managing Partner  
04/11/2023

Qiming U.S. Healthcare GP II, LLC, By /s/ Mark McDade, Managing Partner  
04/11/2023

/s/ Mark McDade  
04/11/2023

/s/ Gary Rieschel  
04/11/2023

**Signature of Reporting Person**  
Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.